The Global Ophthalmic Ultrasound Systems Market is projected to grow at a CAGR of 8.16% during the forecast period to reach US$4.670 billion by 2029, from US$2.700 billion in 2022.
Ophthalmic ultrasound systems are specialized medical devices used in ophthalmology for diagnostic imaging and therapeutic purposes. These systems utilize high-frequency sound waves to create detailed images of the eye's internal structures, including the cornea, lens, vitreous humor, and retina. Ophthalmic ultrasound is particularly valuable in cases where traditional imaging techniques, such as optical coherence tomography (OCT) or fundus photography, may be insufficient due to factors like opacities in the eye's media or poor visualization of the posterior segment.
Ophthalmic ultrasound can aid in the diagnosis and management of various eye conditions, such as retinal detachment, intraocular tumors, vitreous hemorrhage, and glaucoma. Additionally, ultrasound biomicroscopy (UBM) is a specialized form of ophthalmic ultrasound used for high-resolution imaging of anterior segment structures like the iris, ciliary body, and angle. Ophthalmic ultrasound systems play a crucial role in the comprehensive evaluation and treatment of ocular diseases, contributing to improved patient care and outcomes in ophthalmology practice.
Besides, the WHO evaluated that around 826 million individuals around the world are influenced by unaddressed presbyopia. Refractive errors, age-related macular degeneration, cataracts, and glaucoma are recognized as the major causes of vision disability and visual impairment all over the world, with vision loss influencing people of different ages, though transcendently those above fifty years of age. These discoveries emphasize the expanding burden of eye illnesses universally, driving the demand for ophthalmic ultrasound devices market, which are pivotal for diagnosing such conditions.
Additionally, diabetic retinopathy affects approximately 93 million individuals globally. Among individuals with type 1 diabetes, the prevalence of diabetic retinopathy is 77.3%, while for those with type 2 diabetes, it is 25.1%. It is estimated that 25% to 30% of type 2 diabetes patients will develop vision-threatening diabetic macular edema. Laser therapy is required for 5% to 8% of patients with diabetic retinopathy.
For illustration, there are around 12 million adults that are aged forty and over in the US who have vision loss that cannot be rectified, with over 1 million of them classified as blind. It is anticipated that the number of blind people will surge to 8.96 million by 2050, to a great extent due to the rising predominance of diabetes and other chronic ailments, as well as the elderly population within the United States. Besides, the Centers for Disease Control and Prevention (CDC) report that about 3% of children below the age of 18 years encounter visual impairment or blindness.
Moreover, over 8 million Canadians, about 3.1 million in Ontario, are influenced by one of the four fundamental eye illnesses (age-related macular degeneration, glaucoma, diabetic retinopathy, and cataracts), putting them at the chance of vision loss or now encountering it. The expanding predominance of eye disorders is anticipated to drive share for the ophthalmic ultrasound systems market and hence fuel industry expansion.
Ophthalmic ultrasound systems are specialized medical devices used in ophthalmology for diagnostic imaging and therapeutic purposes. These systems utilize high-frequency sound waves to create detailed images of the eye's internal structures, including the cornea, lens, vitreous humor, and retina. Ophthalmic ultrasound is particularly valuable in cases where traditional imaging techniques, such as optical coherence tomography (OCT) or fundus photography, may be insufficient due to factors like opacities in the eye's media or poor visualization of the posterior segment.
Ophthalmic ultrasound can aid in the diagnosis and management of various eye conditions, such as retinal detachment, intraocular tumors, vitreous hemorrhage, and glaucoma. Additionally, ultrasound biomicroscopy (UBM) is a specialized form of ophthalmic ultrasound used for high-resolution imaging of anterior segment structures like the iris, ciliary body, and angle. Ophthalmic ultrasound systems play a crucial role in the comprehensive evaluation and treatment of ocular diseases, contributing to improved patient care and outcomes in ophthalmology practice.
Market Drivers:
Increasing optical disorders are expected to propel the ophthalmic ultrasound systems market growth.
The increasing predominance of optical illnesses like nearsightedness, hyperopia, astigmatism, and presbyopia around the world is predicted to boost the ophthalmic ultrasound systems market expansion within the estimated period. For instance, as per the World Health Organization's data of October 2021, around 2.2 billion people globally endure close or far-off vision disability, approximately 1 billion cases being preventable or however to be tended to.Besides, the WHO evaluated that around 826 million individuals around the world are influenced by unaddressed presbyopia. Refractive errors, age-related macular degeneration, cataracts, and glaucoma are recognized as the major causes of vision disability and visual impairment all over the world, with vision loss influencing people of different ages, though transcendently those above fifty years of age. These discoveries emphasize the expanding burden of eye illnesses universally, driving the demand for ophthalmic ultrasound devices market, which are pivotal for diagnosing such conditions.
The increasing prevalence of diabetic retinopathy is anticipated to increase the demand for ophthalmic ultrasound systems.
The prevalence of diabetic retinopathy is one of the major causes for the market expansion in the year ahead. For instance, recent data from the American Academy of Ophthalmology indicates that there are around 387 million individuals worldwide living with diabetes mellitus in the year 2016, which is expected to expand to 592 million by 2035.Additionally, diabetic retinopathy affects approximately 93 million individuals globally. Among individuals with type 1 diabetes, the prevalence of diabetic retinopathy is 77.3%, while for those with type 2 diabetes, it is 25.1%. It is estimated that 25% to 30% of type 2 diabetes patients will develop vision-threatening diabetic macular edema. Laser therapy is required for 5% to 8% of patients with diabetic retinopathy.
North America is expected to hold a substantial portion of the market.
Variables like increasing awareness, rising disposable incomes, a developing elderly populace, and the predominance of eye conditions are growing market extensions within North America. Several research article highlights on the predominance of visual impairment and other visual disorders.For illustration, there are around 12 million adults that are aged forty and over in the US who have vision loss that cannot be rectified, with over 1 million of them classified as blind. It is anticipated that the number of blind people will surge to 8.96 million by 2050, to a great extent due to the rising predominance of diabetes and other chronic ailments, as well as the elderly population within the United States. Besides, the Centers for Disease Control and Prevention (CDC) report that about 3% of children below the age of 18 years encounter visual impairment or blindness.
The rise in undiagnosed target diseases is additionally anticipated to contribute to market expansion.
Further, the Ontario Association of Optometrists article in July 2021 stated the effect of Canada's aging populace on the predominance of corrected vision. The report shown that 1.2 million Canadians encounter vision loss, with 466,000 dwelling in Ontario alone.Moreover, over 8 million Canadians, about 3.1 million in Ontario, are influenced by one of the four fundamental eye illnesses (age-related macular degeneration, glaucoma, diabetic retinopathy, and cataracts), putting them at the chance of vision loss or now encountering it. The expanding predominance of eye disorders is anticipated to drive share for the ophthalmic ultrasound systems market and hence fuel industry expansion.
Market Developments:
- April 2024-Warburg Pincus bought a stake in Appasamy Associates, India's largest ophthalmic equipment and intraocular lens manufacturer. This is the largest healthcare sector investment by the firm in India. Appasamy's strong R&D capabilities and vertical integration enable it to offer products at affordable prices.
- February 2023-NIDEK launched the Cube α Ophthalmic Surgical System, a new ultrasound technology that enhances phacoemulsification and surgical safety. The system, designed with Gyro torsional technology, ensures efficient delivery of ultrasound energy, particularly for moderate cataracts, and protects intraocular tissues, making it a valuable addition to the ophthalmic surgical equipment range.
- October 2022-Halma purchased IZI Medical Product for approximately EUR 138 million (equivalent to USD 145 million). This acquisition aims to enhance its footprint in various diagnostic and therapeutic procedures.
- March 2022-Lumibird Medical opened a subsidiary in Mumbai, Lumibird Medical India, to boost sales of Quantel Medical and Ellex products in India. The subsidiary aims to provide a shared range of ultrasound platforms, ophthalmic lasers, and equipment for dry eye diagnosis and treatment.
Company Product:
- On-platform ultrasound system XBit 90- The XBit 90 is a premium ultrasound system by CHISON Medical Technologies, featuring the latest NIT platform and advanced features such as Shear Wave Elastography, Elastography, SonoCrystal, and strain and strain ratio measurements. It offers multi-modality imaging and can be used in various fields such as OB/GYN, cardiovascular, MSK, critical care, emergency medicine, anesthesia, and pediatrics. The system offers various imaging modes, including B/W, color Doppler, 3D/4D, spectral Doppler, elastography, and needle guidance. It also offers built-in consoles and touchscreen options and can be used for various probe types.
- Ezer Ultrasonic A/B scanner EUS-2600- The Ezer EUS-2600 Ultrasonic A/B scanner by US Ophthalmic offers multiple TGC options, real-time image/video capture, a large 12.1" LCD touchscreen display, user-friendly clinical reporting, automatic AL acquisition, PDF reports, interfaces like HDMI and DICOM 3.0 protocol, and a massive storage capacity for over 20,000 exams. It also features a high-definition 20MHz B-Scan probe and a Dist-5 immersion method.
Market Segmentation:
Global Ophthalmic Ultrasound Systems Market is segmented and analyzed as below:By Type
- A-Scan
- B-Scan
- Combined Scan
- Pachymeter
- Ultrasound Bio-microscopy (UBM)
By Portability
- Portable Ophthalmic Ultrasound Systems
- Standalone Ophthalmic Ultrasound Systems
By End-user
- Hospitals
- Ophthalmology Clinics
- Others
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Others
Table of Contents
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
5. GLOBAL OPHTHALMIC ULTRASOUND SYSTEMS MARKET BY TYPE
6. GLOBAL OPHTHALMIC ULTRASOUND SYSTEMS MARKET BY PORTABILITY
7. GLOBAL OPHTHALMIC ULTRASOUND SYSTEMS MARKET BY END-USERS
8. GLOBAL OPHTHALMIC ULTRASOUND SYSTEMS MARKET BY GEOGRAPHY
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
10. COMPANY PROFILES
Companies Mentioned
- Sonomed Escalon
- Halma plc
- Appasamy Associates
- DGH Technology Inc.
- Ellex Medical Lasers Ltd
- Quantel Medical
- Nikon Corporation (Optos Plc)
- NIDEK CO
- Micro Medical Devices, Inc.
- MEDA Co., Ltd
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 124 |
Published | May 2024 |
Forecast Period | 2022 - 2029 |
Estimated Market Value ( USD | $ 2.7 Billion |
Forecasted Market Value ( USD | $ 4.67 Billion |
Compound Annual Growth Rate | 8.1% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |